Veru (VERU) Q3 FY26 earnings call

Veru, a late clinical-stage biopharmaceutical company, is advancing its lead asset enobosarm for sarcopenic obesity, focusing on preserving lean mass and physical function in older patients receiving GLP-1 agonists. The company achieved a significant milestone with full enrollment of its Phase IIb PLATEAU study and secured a key method-of-use patent for enobosarm, while also establishing a supply agreement with Novo Nordisk. This quarter highlights strategic progress in clinical development and intellectual property, positioning enobosarm for a differentiated role in the expanding obesity mark